Myoscience said it landed $8.4 million of a hoped-for $11.5 million for a device that applies extreme cold to the skin as a way to temporarily treat pain and smooth wrinkles.
Founded in 2005, Myoscience had previously disclosed $97 million in funding, with current investors including De Novo Ventures, Accuitive Medical Ventures, Medicis, NMP, Saratoga Ventures and Valiance.
De Novo Ventures cofounder Rich Ferrari is acting as interim CEO of Myoscience, having replaced former CEO Clint Carnell, who joined Myoscience in 2011 and who was formerly a sales executive with Bausch & Lomb.
Help employers find you! Check out all the jobs and post your resume.
